CA-DC-CONNECTED-CAR
7.8.2024 11:01:34 CEST | Business Wire | Press release
DC Connected Car GmbH, a trailblazer in AI-driven remote vehicle diagnostics, announces the closure of a €2.1M seed funding round. Led by Insurtech-fund VENPACE, this round includes contributions from Borusan Ventures, Atlas Ventures, Network.VC, and existing investors APX, Bloomhaus Ventures, and Business Angels. This investment accelerates DC Connected Car's mission to revolutionize the $500B automotive aftersales market with its virtual technician platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807187434/en/
This fresh injection of capital will fuel DC Connected Car's international expansion and development of advanced diagnostic tools for roadside assistance, warranty, and repair. (Graphic: Business Wire)
DC Connected Car's virtual technician platform addresses the shortage of skilled labor in the industry, and their remote diagnostics and advanced AI set new sector benchmarks. Unlike conventional diagnostics, AI-driven solutions deliver automated, intelligent insights into vehicle health and performance, providing real-time problem-solution recommendations. This approach minimizes the need for physical inspections/repairs, but also integrates into customers' lives by offering remote support. By combining AI with remote diagnostics, DC Connected Car redefines vehicle maintenance and customer convenience, solidifying its position as a standout player in the space, highlighted by its partnerships with Major OEMs.
"AI has the potential to revolutionize various automotive areas that Borusan operates in, such as aftersales, fleets, and used car business," said Timo Kilp, Head of Borusan Ventures. "We believe DC Connected Car's AI-driven digital technician holds significant promise to accelerate the diagnosis and repair of vehicle issues, further enhancing our customer service."
Not only disruptive in the automotive repair sector, DC Connected Car is driving innovations in the insurance industry too. Their partnership with Real Garant Versicherung AG marks a new era of digitalization, sustainable mobility, and future-orientated service design.
"With the cooperation with DC Connected Car GmbH, we expect to significantly contribute to environmentally friendly mobility solutions and to drive forward digitalization in the automotive sector by providing digital solutions for warranty and service products,” explains Suzana Janny, Head of Market Proposition at Real Garant Versicherung AG.
This fresh injection of capital will fuel DC Connected Car's international expansion and development of advanced diagnostic tools for roadside assistance, warranty, and repair. The company has seamlessly integrated and digitized expertise across various automotive departments, breaking down silos and enhancing efficiency.
About DC Connected Car GmbH
Founded in 2020 in Leibi, Germany, DC Connected Car offers an all-in-one solution that represents the virtual vehicle technician of the future. This platform addresses the complexities of modern vehicle generations and labor shortage by enabling automated and intelligent diagnostic and repair processes.
"What excites us most about DC Connected Car is the wide range of possible applications for their virtual assistant in the mobility ecosystem. Insurers especially have a high interest in elevating their customer experience by digitizing roadside assistance services. In addition, the team has already impressively demonstrated that it has been able to win well-known B2B customers and OEMs as partners," said Tizian Hoppen of VENPACE.
The team behind DC Connected Car includes experts with deep industry knowledge and experience. Dennis Christ, an expert in automotive technology and a certified appraiser, provides precise and reliable diagnostic procedures. Ralf Schollenberger leverages his extensive network and expertise in insurance and the aftermarket to forge strategic partnerships. Willian Servigna, specializing in AI and software development, ensures that solutions remain at the forefront of technology.
About VENPACE - VENPACE is a leading investor from the insurance space, guiding startups with unique expertise to sustainably scale innovative solutions. Together with partners throughout the DACH region, they tackle the insurance industry’s challenges head-on, developing and establishing innovative business models.
About BORUSAN Ventures - Borusan Ventures is the corporate venture capital arm of Borusan Group, a prominent industrial group in the U.S., Europe and CIS region. Headquartered in Silicon Valley, Borusan Ventures invests in early-stage startups in the U.S. and Europe, focusing on mobility, supply chain/logistics, energy/climate, enterprise, and industrial sectors.
About ATLAS Ventures - Atlas Ventures is a UK-based industrial tech fund focussed on investing in seed and late seed stage opportunities in Developed European markets, with a primary focus on innovative B2B solutions targeting industrial manufacturing, energy and climate, mobility, supply chain and logistics sectors.
For more information, visit https://www.dc-connected.de/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807187434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 15:00:00 CET | Press release
Renowned optimization and AI technologies leader to advance hybrid approaches for demanding decision challenges. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remai
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 14:00:00 CET | Press release
Alliance Brings Seamless Integration of Asset Data into ArcGIS for PIX4Dcatch Users Pix4D joins with Esri to launch new terrestrial scanning workflow for infrastructure-focused organizations. Esri and Pix4D workflow lets field teams capture accurate 3D models and augmented reality using PIX4Dcatch app data integrated directly into ArcGIS Online in real time. New integration enables users to document subsurface assets with seamless precision. Workflow brings high-fidelity, georeferenced documentation and instant verification to the project lifecycle for improved accuracy. Explore the PIX4Dcatch app and publish 3D data to ArcGIS Online. Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Es
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 14:00:00 CET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release
Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa
BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 12:00:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom